VTechWorks staff will be away for the Thanksgiving holiday beginning at noon on Wednesday, November 27, through Friday, November 29. We will resume normal operations on Monday, December 2. Thank you for your patience.
 

Modeling-Enabled Characterization of Novel NLRX1 Ligands

Simple item page
dc.contributor.authorLu, Pinyien
dc.contributor.authorHontecillas, Raquelen
dc.contributor.authorAbedi, Vidaen
dc.contributor.authorKale, Shiv D.en
dc.contributor.authorLeber, Andrewen
dc.contributor.authorHeltzel, Chaseen
dc.contributor.authorLangowski, Marken
dc.contributor.authorGodfrey, Victoriaen
dc.contributor.authorPhilipson, Casandraen
dc.contributor.authorTubau-Juni, Nuriaen
dc.contributor.authorCarbo, Adriaen
dc.contributor.authorGirardin, Stephenen
dc.contributor.authorUren, Aykuten
dc.contributor.authorBassaganya-Riera, Josepen
dc.date.accessioned2018-09-07T14:37:52Zen
dc.date.available2018-09-07T14:37:52Zen
dc.date.issued2015-12-29en
dc.description.abstractNucleotide-binding domain and leucine-rich repeat containing (NLR) family are intracellular sentinels of cytosolic homeostasis that orchestrate immune and inflammatory responses in infectious and immune-mediated diseases. NLRX1 is a mitochondrial-associated NOD-like receptor involved in the modulation of immune and metabolic responses. This study utilizes molecular docking approaches to investigate the structure of NLRX1 and experimentally assesses binding to naturally occurring compounds from several natural product and lipid databases. Screening of compound libraries predicts targeting of NLRX1 by conjugated trienes, polyketides, prenol lipids, sterol lipids, and coenzyme A-containing fatty acids for activating the NLRX1 pathway. The ligands of NLRX1 were identified by docking punicic acid (PUA), eleostearic acid (ESA), and docosahexaenoic acid (DHA) to the C-terminal fragment of the human NLRX1 (cNLRX1). Their binding and that of positive control RNA to cNLRX1 were experimentally determined by surface plasmon resonance (SPR) spectroscopy. In addition, the ligand binding sites of cNLRX1 were predicted in silico and validated experimentally. Target mutagenesis studies demonstrate that mutation of 4 critical residues ASP677, PHE680, PHE681, and GLU684 to alanine resulted in diminished affinity of PUA, ESA, and DHA to NLRX1. Consistent with the regulatory actions of NLRX1 on the NF-κB pathway, treatment of bone marrow derived macrophages (BMDM)s with PUA and DHA suppressed NF-κB activity in a NLRX1 dependent mechanism. In addition, a series of pre-clinical efficacy studies were performed using a mouse model of dextran sodium sulfate (DSS)-induced colitis. Our findings showed that the regulatory function of PUA on colitis is NLRX1 dependent. Thus, we identified novel small molecules that bind to NLRX1 and exert anti-inflammatory actions.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0145420en
dc.identifier.eissn1932-6203en
dc.identifier.issue12en
dc.identifier.othere0145420en
dc.identifier.pmid26714018en
dc.identifier.urihttp://hdl.handle.net/10919/84973en
dc.identifier.volume10en
dc.language.isoenen
dc.publisherPLOSen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.titleModeling-Enabled Characterization of Novel NLRX1 Ligandsen
dc.title.serialPLOS ONEen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
journal.pone.0145420.PDF
Size:
2.65 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Works, Fralin Life Sciences Institute